Aarkstore Enterprise---johnson & Johnson (jnj) - Financial And Strategic Analysis Review

Share:    

Johnson & Johnson (J&J) is engaged in the manufacture and sale of a broad range of healthcare products worldwide

. The company focuses on the development of products related to health and well-being. J&J operates through three business segments, namely, Consumer, Pharmaceuticals, and Medical Devices and Diagnostics. The companys Consumer segment offers a wide range of health and personal care products in the beauty, oral care, baby care, womens health and over-the-counter categories. Through its Pharmaceuticals segment, the company focuses on five therapeutic areas, namely, Neuroscience, Cardiovascular Disease and Metabolism, Immunology, Oncology and Infectious Disease.

Table of Contents :

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Section 1 - About the Company 5

Johnson & Johnson - Key Facts 5

Johnson & Johnson - Key Employees 6

Johnson & Johnson - Key Employee Biographies 7

Johnson & Johnson - Major Products and Services 8

Johnson & Johnson - History 11

Johnson & Johnson - Company Statement 15

Johnson & Johnson - Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Section 2 - Company Analysis 28

Johnson & Johnson - Business Description 28

Business Description - Consumer 28

Consumer - Overview 28

Consumer - Financials 28

Consumer - Market View 29

Consumer - Key Strategies 29

Consumer - Technology 29

Business Description - Medical Devices and Diagnostics 29

Medical Devices and Diagnostics - Overview 29

Medical Devices and Diagnostics - Financials 29

Medical Devices and Diagnostics - Market View 29

Medical Devices and Diagnostics - Key Strategies 30

Medical Devices and Diagnostics - Technology 30

Business Description - Pharmaceutical 30

Pharmaceutical - Overview 30

Pharmaceutical - Financials 30

Pharmaceutical - Market View 30

Pharmaceutical - Key Strategies 31

Pharmaceutical - Technology 31

Johnson & Johnson - SWOT Analysis 32

SWOT Analysis - Overview 32

Johnson & Johnson - Strengths 32

Strength - Strong Liquidity Position 32

Strength - Diversified Product Offerings 32

Strength - Widespread Geographical Presence 32

Strength - Strong In-house Research Capabilities 33

Johnson & Johnson - Weaknesses 33

Weakness - Illegal Promotion of Topamax 33

Weakness - Declining Market Share in the Sector 33

Weakness - Underperforming Pharmaceuticals Segment 33

Weakness - Patent Expiries 34

Weakness - Product Recalls 34

Johnson & Johnson - Opportunities 34

Opportunity - Changing Demographics 34

Opportunity - Growth in the Prevalence of Cancer 34

Opportunity - Global Pharmaceutical Market 35

Opportunity - New Product Launches and Strong Pipeline 35

Opportunity - Strategic Acquisitions 35

Johnson & Johnson - Threats 36

Threat - Increased Pricing Control 36

Threat - Competitive Pressures 36

Threat - Regulatory Requirements 36

Threat - Litigation and Legal Claims 36

Johnson & Johnson - Key Competitors 37

Section 3 - Company Financial Ratios 38

Financial Ratios - Capital Market Ratios 38

Financial Ratios - Annual Ratios 38

Performance Chart 40

Financial Performance 40

Financial Ratios - Interim Ratios 41

Financial Ratios - Ratio Charts 42

Section 4 - Companys Recent Developments 43

Jul 20, 2010: Johnson & Johnson Reports Sales Of $15.33 Billion In Q2 2010 43

Jul 20, 2010: Johnson & Johnson Reports Net Income Of $3.4 billion For Q2 2010 43

Jul 19, 2010: FDA Inspects J&Js Lancaster Manufacturing Unit 43

Jul 19, 2010: Johnson & Johnson Appoints E. L. Davis To Board 43

Jul 19, 2010: Johnson & Johnson Appoints Ian Davis To Board 44

Jul 15, 2010: J&J To Cut 300 Jobs At Pennsylvania Facility 44

Jun 03, 2010: Johnson & Johnson Highlights Growth Strategies For MD&D Segment 44

Apr 20, 2010: J&J Announces Rejection Of Application For Sedasys System By FDA And Provides Updates Of Pipeline Products 46

Apr 20, 2010: J&J Q1 Sales Increase Due To Favourable Currency Exchange Rates 46

Apr 20, 2010: Johnson & Johnson Reports Net Earnings Of $4.5 Billion In Q1 2010 46

Section 5 - Appendix 48

Methodology 48

Ratio Definitions 48

About GlobalData 52

Contact Us 52

For more information please contact :

http://www.aarkstore.com/reports/Johnson-Johnson-JNJ-Financial-and-Strategic-Analysis-Review-62675.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by: Aarkstore Enterprise

POST COMMENT

Aarkstore Enterprise---synthes, Inc. (syst) - Financial And Strategic Analysis Review Aarkstore Enterprise---smith & Nephew Plc (sn.) - Financial And Strategic Analysis Review Aarkstore Enterprise---davita Inc. (dva) - Financial And Strategic Analysis Review Aarkstore Enterprise---edwards Lifesciences Corporation (ew) - Financial And Strategic Analysis Revi Aarkstore Enterprise---fresenius Se (freg) - Financial And Strategic Analysis Review Aarkstore Enterprise---haemonetics Corporation (hae) - Financial And Strategic Analysis Review Aarkstore Enterprise---hanger Orthopedic Group, Inc. (hgr) - Financial And Strategic Analysis Review The Exciting World Of Day Trading Promoting Heavy Before The Holidays Not Just For Retailers Green Unicolor Lycra Spandex Zentai Suit, Wholesale Green Spandex Suit Black With Green Lycra Spandex Zentai Costume, Wholesale Green Spandex Suit Back Testing Trading Systems - Four Facts You Should Know Green And Black Shiny Metallic Unisex Zentai Suit, Wholesale Green And Black Zentai